Plasmablastic lymphoma in Johannesburg, South Africa, in the era of widescale antiretroviral therapy use.
HIV-associated lymphoma
antiretroviral therapy
plasmablastic lymphoma
Journal
HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
29
04
2020
revised:
20
07
2020
accepted:
26
08
2020
pubmed:
7
10
2020
medline:
15
3
2022
entrez:
6
10
2020
Statut:
ppublish
Résumé
Plasmablastic lymphoma (PBL) is a clinically aggressive lymphoma which has a predilection for extranodal sites and is frequently HIV-associated. The incidence of non-Hodgkin lymphoma is thought to be reduced by widescale antiretroviral therapy (ART) coverage, but the literature is sparse as regards the impact of ART on the incidence of PBL and its outcomes in South Africa (SA). This study aimed to compare factors of interest in cases of PBL diagnosed before and after the widespread availability of ART in Johannesburg, SA. All cases of PBL diagnosed in the state sector hospitals of Johannesburg in 2007 and 2017 (before and after the widespread availability of ART, respectively) were extracted from the laboratory information system, and factors of interest compared. The majority (> 95%) of cases of PBL were seen among people with HIV infection (PWH) at both time-points, and the proportion of patients on ART and with virological suppression (VS) increased significantly in 2017. However, the number of cases of PBL did not differ significantly between the two years assessed, comprising 46/397 (11.6%) and 53/582 (9.6%) of all lymphomas in 2007 and 2017, respectively (P = 0.23). Ongoing risk for PBL among PWH with virological control and immunological recovery was evident in 2017, as 18.9% of the patients had both VS and CD4 counts > 200 cells/μL at diagnosis. Inferior survival times were associated with elevated lactate dehydrogenase (LDH) levels and Epstein Barr virus (EBV) negativity, but were not influenced by the presence of AIDS, ART or VS. EBV negativity was significantly associated with VS, and appeared to flag a particularly aggressive form of the disease. Widescale ART coverage has not reduced the incidence of PBL in Johannesburg, and an ongoing risk for this disease among PWH with adequate virological control and immunological recovery persists.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
225-230Informations de copyright
© 2020 British HIV Association.
Références
Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood 2015; 125 (15): 2323-2330.
Stein H, Campo E, Harris NL. WHO classification of tumors of the haematopoietic and lymphoid tissues. Lyon, IARC, 2017.
Castillo JJ, Winer ES, Stachurski D et al. Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma. Oncologist 2010; 15 (3): 293-299.
Castillo JJ, Furman M, Beltran BE et al. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Cancer 2012; 118 (21): 5270-5277.
Schommers P, Wyen C, Hentrich M et al. Poor outcome of HIV-infected patients with plasmablastic lymphoma: results from the German AIDS-related lymphoma cohort study. AIDS 2013; 27 (5): 842-845.
Morscio J, Dierickx D, Nijs J et al. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases. Am J Surg Pathol 2014; 38 (7): 875-886.
Castillo JJ, Winer ES, Stachurski D et al. Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. Leuk Lymphoma 2010; 51 (11): 2047-2053.
Teruya-Feldstein J, Chiao E, Filippa DA et al. CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patients. Ann Oncol 2004; 15 (11): 1673-1679.
Tchernonog E, Faurie P, Coppo P et al. Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group. Ann Oncol 2017; 28 (4): 843-848.
Wiggill TM, Mantina H, Willem P, Perner Y, Stevens WS. Changing pattern of lymphoma subgroups at a tertiary academic complex in a high-prevalence HIV setting: a South African perspective. J Acquir Immune Defic Syndr 2011; 56 (5): 460-466.
UNAIDS. https://www.unaids.org/en/resources/documents/2019/HIV_estimates_with_uncertainty_bounds_1990-present (accessed 03 September 2019).
Johnson LF. Access to antiretroviral treatment in South Africa, 2004-2011. South Afr J HIV Med 2012; 13 (1): 22-27.
Carroll V, Garzino-Demo A. HIV-associated lymphoma in the era of combination antiretroviral therapy: shifting the immunological landscape. Pathog Dis 2015; 73 (7):1-7.
Kroeze S, Ondoa P, Kityo CM et al. Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa. AIDS 2018; 32 (8): 1043-1051.
Noy A, Chadburn A, Lensing SY, Moor P. Plasmablastic lymphoma is curable the HAART Era. A 10 year retrospective by the AIDS malignancy consortium (AMC) [abstract]. Blood 2013; 122 (21): 1801.
Cattaneo C, Re A, Ungari M et al. Plasmablastic lymphoma among human immunodeficiency virus-positive patients: results of a single center's experience. Leuk Lymphoma 2015; 56 (1): 267-269.
Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol 2008; 83 (10): 804-809.
da Silva SR, de Oliveira DE. HIV, EBV and KSHV: viral cooperation in the pathogenesis of human malignancies. Cancer Lett 2011; 305 (2): 175-185.